Immuno Vaccine Inc (IMMVF) 0.5300 $IMMVF Immunovaccine

New Post Public Reply Private Reply Replies (0) Message Board

Jun 8, 2016 at 2:00 PM

Immuno Vaccine Inc (IMMVF) 0.5300 $IMMVF

Immunovaccine Announces Preclinical Collaboration for DepoVax(TM)-Based Malaria Vaccine
Marketwire Canada - Thu Jun 02, 6:06AM CDT
Initial Study Conducted With The University of Edinburgh to Examine Vaccine Candidate's Effects on Malaria Parasites Linked to Most Severe Form of the Disease
IMV.TO: 0.62 (-0.01)

Immunovaccine Announces Financial Results for Quarter Ended March 31, 2016
Marketwire Canada - Tue May 10, 4:06PM CDT
HALIFAX, NOVA SCOTIA--(Marketwired - May 10, 2016) - Immunovaccine Inc. ("Immunovaccine" or the "Company"

(TSX:IMV) (OTCQX:IMMVF), a clinical-stage vaccine and immunotherapy company, today released its financial and operational results for the first quarter ended March 31, 2016.
IMV.TO: 0.62 (-0.01), INCY: 83.25 (+0.81), LDOS: 49.48 (+0.18)

Immunovaccine Launches DPX-NEO Program to Develop Patient-Specific Neoepitope Immunotherapies
Marketwired - Thu May 05, 6:06AM CDT
HALIFAX, NOVA SCOTIA--(Marketwired - May 5, 2016) - Immunovaccine Inc. ("Immunovaccine" or the "company"

(TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced the launch of its DPX-NEO program to develop neoepitope immunotherapies to further expand the immuno-oncology applications for its DepoVax™-based vaccines. As its first official partnership for this program, Immunovaccine will collaborate with experts in this field at UConn Health on a preclinical study to evaluate the immunologic and anti-tumor activity of patient-specific neoepitopes.
IMV.TO: 0.62 (-0.01)

Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference
Marketwired - Thu Apr 28, 6:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company"

(TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, announced that Chief Executive Officer Frederic Ors will present an update on the Company's recent progress and future strategy at the 2016 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Tuesday, May 3, 2016 at 3:00 p.m. Eastern Time.
IMV.TO: 0.62 (-0.01)

New Preclinical Study Shows Immunovaccine's DepoVax(TM)-Based Cancer Vaccine May Improve Efficacy of Checkpoint Inhibitors
Marketwired - Wed Apr 20, 6:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company"

(TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2016. The investigators' findings showed that a combination immunotherapy using a DepoVax(TM)-based vaccine could enhance the anti-tumor effects of a PD-1 blockade, controlling growth in advanced HPV-expressing tumors in animal models.
IMV.TO: 0.62 (-0.01)

Immunovaccine Elects Medicago CEO Andy Sheldon as Board Chairman; Reports Results of the Annual General Meeting (AGM)
Marketwired - Fri Apr 15, 6:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company"

(TSX: IMV) (OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today elected Andrew Sheldon as chairman of its board of directors. Mr. Sheldon, who currently serves as President and CEO of Medicago, joined the board after the company's annual and special meeting of shareholders. Newly named Chief Executive Officer Frederic Ors was also elected to the board.
IMV.TO: 0.62 (-0.01)

Immunovaccine Names Frederic Ors Chief Executive Officer; Andy Sheldon, Medicago CEO, to Join Board of Directors
Marketwired - Wed Apr 13, 6:05AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company"

(TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced that Frederic Ors has been appointed Chief Executive Officer. He and Andy Sheldon, President and CEO of Medicago, will be nominated to the board of directors at the Company's AGM on April 14, and the Board will recommend their election.
IMV.TO: 0.62 (-0.01)

Immunovaccine to Present New Pre-Clinical Data at the 2016 AACR Annual Meeting
Marketwired - Mon Apr 11, 4:05PM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company"

(TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, announced that new pre-clinical data on DPX(TM)-based cancer vaccines will be presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, which be held in New Orleans, Louisiana, April 16-20, 2016.
IMV.TO: 0.62 (-0.01)

Immunovaccine and Leidos Join Forces to Develop a Zika Virus Vaccine Candidate
Marketwired - Thu Apr 07, 6:05AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company"

(TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, and Leidos (NYSE: LDOS), a health, national security and infrastructure solutions company, today announced they will collaborate on developing a vaccine against the mosquito-borne Zika virus and infection, which may be linked to neurological birth defects.
IMV.TO: 0.62 (-0.01), LDOS: 49.48 (+0.18)

Immunovaccine Announces 2015 Year-End Results
Marketwired - Tue Mar 29, 4:06PM CDT
Immunovaccine Inc. (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced its financial and operational results for the year ended December 31, 2015.
IMV.TO: 0.62 (-0.01), INCY: 83.25 (+0.81)

Pipeline of Genital Herpes Market Covering 19 Companies and 17 Drug Profiles
PR Newswire - Thu Mar 24, 1:00AM CDT
New market research report titled "Genital Herpes - Pipeline Review, H2 2015" enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
IMDZ: 11.85 (+0.03), FOMX: 7.13 (+0.02), GNCA: 4.46 (-0.18), NNVC: 1.89 (unch)

Immunovaccine Announces Management Team Changes
Marketwired - Tue Mar 15, 4:05PM CDT
Immunovaccine Inc. ("Immunovaccine" or the "Company"

(TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced that Marc Mansour, Ph.D., will step down as Chief Executive Officer, effective on March 31, 2016 after 14 years with the company. Frederic Ors, Chief Business Officer (CBO), has been named Acting Chief Executive while the company conducts a search for Dr. Mansour's replacement.
IMV.TO: 0.62 (-0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Balancing Rigor and Interests in Education: Insights

Education: A Balancing Act of Academics and Interests So here's the deal, folks. Education isn't just about hitting the textbooks and acing exams. It's a wild dance—balancing rigorous academics and the extracurricular hustle. Brent Reckman, the brains behind The Academy of Charter Schools in Westminster, Colorado, knows this orchestra well. In a feature with...

Matthew Callstrom Named CEO: Mayo Clinic's Next Era

Leadership Change at Mayo Clinic: A Turning Point The Mayo Clinic, a titan in healthcare lands, is on the cusp of a major leadership switch-up. As the trustees hand the reins to Dr. Matthew R. Callstrom, they're banking on a rich blend of experience and visionary thinking to steer their ship. We're looking at what this change might spell for Mayo's storied mission. Who is...

Missoula Inventor Offers Handy Phone Solution on the Move

Adjustable Convenience for the Modern Commuter When you're commuting or just lounging around, less hand strain and more comfort sounds like a no-brainer, right? Well, an inventive soul from Missoula, Montana, just might have cracked this little nut with a gizmo they're calling the COMMUTER PHONE. Imagine never having to juggle your phone during those bumpy moments on the...

Common ADHD Accommodations Fail to Boost Performance

Rethink ADHD Accommodations When it comes to ADHD, everyone ties the classic school accommodations to success. You give kids extra time, a quieter spot, and regular breaks, and you figure that's the magic formula, right? Well, hold onto your hats, because a fresh study out of Florida International University is flipping that script. Turns out, all those accommodations we...

Timken Maintains Robust Dividend Streak in 2026

Timken Keeps Dividend Train Rolling You want to talk consistency? Timken Company just declared its quarterly dividend like clockwork. As a stockholder, that might just be your morning coffee fix before anything else. Notably, Timken's been on the NYSE since 1922, having cranked out 418 consecutive dividend payouts. That's like your grandpa never missing a Sunday golf...

AI Deception Challenges the Confidence of Fraud Defenses

Fraud Week Spotlights AI Deception Alright, here's the rub: we're in Fraud Week 2026, and boy, is AI shaking the foundations of yesterday's fraud defenses! With all this AI talk, you would expect systems to be near invincible by now. But reality? A different beast altogether. AI has this knack of tripling up the complexity while pretending to solve it, making traditional...

Gemmy's Holiday Lights: Bright Ideas for 2026

Deep in the heart of Dallas, Gemmy Industries is out to sprinkle a bit of magic over the holiday season for 2026. This ain't your grandma's string lights we're talkin' about here. We're diving headfirst into a new world of seasonal decor with tech-driven lights that look like they came straight outta a winter wonderland. And hey, if Walmart's set to host this lineup, you...

Surprising Week on Wall Street: Chips Drive Gains

A Wild Week in Wall Street Well, folks, what a week it’s been on Wall Street. The indexes danced the cha-cha, making gains despite closing Friday on a lower note. Despite the retreat, we've got ourselves a week where the major indexes closed higher than the previous Friday. It's not the usual story, but who ever thought stocks played by the rules? The Nasdaq Composite...

vVARDIS Readies for Big Day on NYSE—IPO Set to Shine

vVARDIS Stepping into the Spotlight of the NYSE Alright, folks, here's one that could make some waves. vVARDIS is gearing up for its NYSE debut, trading under the ticker VVVV. They're no small fry talking about 9.72 million shares priced at 18 bucks a pop. This isn't just any run-of-the-mill company; they claim to have the first peptide-containing formulation for early...

55 Broad Street's New Face: A $500M Revamp with RXR

Recapitalization: Changing the Game for 55 Broad Street Here we are again, watching yet another iconic Manhattan building redefine itself. This time, it's 55 Broad Street's turn, as Silverstein, MetroLoft, and RXR shake things up. Newmark Group, Inc. (NASDAQ: NMRK), the fiery real estate power player, orchestrated a dynamic transaction involving a $305 million financing...